Department of Psychiatry, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Department of Psychiatry, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Brain Behav Immun. 2022 Jul;103:50-60. doi: 10.1016/j.bbi.2022.03.013. Epub 2022 Mar 24.
Functional outcomes are important measures in the overall clinical course of psychosis and individuals at clinical high-risk (CHR), however, prediction of functional outcome remains difficult based on clinical information alone. In the first part of this study, we evaluated whether a combination of biological and clinical variables could predict future functional outcome in CHR individuals. The complement and coagulation pathways have previously been identified as being of relevance to the pathophysiology of psychosis and have been found to contribute to the prediction of clinical outcome in CHR participants. Hence, in the second part we extended the analysis to evaluate specifically the relationship of complement and coagulation proteins with psychotic symptoms and functional outcome in CHR.
We carried out plasma proteomics and measured plasma cytokine levels, and erythrocyte membrane fatty acid levels in a sub-sample (n = 158) from the NEURAPRO clinical trial at baseline and 6 months follow up. Functional outcome was measured using Social and Occupational Functional assessment Score (SOFAS) scale. Firstly, we used support vector machine learning techniques to develop predictive models for functional outcome at 12 months. Secondly, we developed linear regression models to understand the association between 6-month follow-up levels of complement and coagulation proteins with 6-month follow-up measures of positive symptoms summary (PSS) scores and functional outcome.
A prediction model based on clinical and biological data including the plasma proteome, erythrocyte fatty acids and cytokines, poorly predicted functional outcome at 12 months follow-up in CHR participants. In linear regression models, four complement and coagulation proteins (coagulation protein X, Complement C1r subcomponent like protein, Complement C4A & Complement C5) indicated a significant association with functional outcome; and two proteins (coagulation factor IX and complement C5) positively associated with the PSS score. Our study does not provide support for the utility of cytokines, proteomic or fatty acid data for prediction of functional outcomes in individuals at high-risk for psychosis. However, the association of complement protein levels with clinical outcome suggests a role for the complement system and the activity of its related pathway in the functional impairment and positive symptom severity of CHR patients.
功能结果是精神病整体临床病程的重要衡量标准,对于处于临床高风险(CHR)的个体也是如此,然而,仅基于临床信息预测功能结果仍然很困难。在本研究的第一部分,我们评估了生物和临床变量的组合是否可以预测 CHR 个体的未来功能结果。补体和凝血途径以前被认为与精神病的病理生理学有关,并发现它们有助于预测 CHR 参与者的临床结果。因此,在第二部分中,我们扩展了分析,以专门评估补体和凝血蛋白与 CHR 患者的精神病症状和功能结果的关系。
我们在 NEURAPRO 临床试验的子样本(n=158)中进行了血浆蛋白质组学和血浆细胞因子水平的测量,并在基线和 6 个月随访时测量了红细胞膜脂肪酸水平。功能结果使用社会和职业功能评估评分(SOFAS)量表进行测量。首先,我们使用支持向量机学习技术为 12 个月时的功能结果开发预测模型。其次,我们开发了线性回归模型,以了解 6 个月时补体和凝血蛋白水平与 6 个月时阳性症状综合评分(PSS)和功能结果的关系。
基于包括血浆蛋白质组、红细胞脂肪酸和细胞因子在内的临床和生物学数据的预测模型,对 CHR 参与者的 12 个月随访时的功能结果预测效果不佳。在线性回归模型中,四种补体和凝血蛋白(凝血蛋白 X、补体 C1r 亚成分样蛋白、补体 C4A 和补体 C5)与功能结果呈显著相关;两种蛋白(凝血因子 IX 和补体 C5)与 PSS 评分呈正相关。我们的研究不支持细胞因子、蛋白质组或脂肪酸数据可用于预测精神病高危个体的功能结果。然而,补体蛋白水平与临床结果的关联表明补体系统及其相关途径的活性在 CHR 患者的功能障碍和阳性症状严重程度中起作用。